Impact BioMedical, Inc. (IBO) Net Asset Value

The price chart for Impact BioMedical Inc (IBO) illustrates the price action of an asset with a market valuation of 0.14. The company is scaling patents in the fields of antivirals and oncology, targeting B2B licensing. Automated screening ensures research efficiency, reducing headcount and accelerating releases. Impact BioMedical Inc (IBO) is currently developing intellectual property in biosecurity, with strategic alliances planned by 2026.

IBO Impact BioMedical Book Capitalization (09/17/2024 - 10/27/2026)

Financial and market metric breakdowns for Impact BioMedical (IBO)

- price and consensus price forecast:
Market Price impactbiomedinc.com|IBO - Price Target Chart
- market capitalization data:
Market Valuation Impact BioMedical, Inc.|IBO - Enterprise Value
- book capitalization data:
Accounting Value of a Share Impact BioMedical|IBO - Book Capitalization|Market Capitalization to Book Value Ratio impactbiomedinc.com|IBO - Aggregate Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Impact BioMedical Inc|IBO - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Impact BioMedical, Inc.|IBO - Company Aggregate Debts|Debts to Book Capitalization Impact BioMedical, Inc.
Fundamental company valuation:Impact BioMedical Inc

Impact BioMedical Inc (IBO) deployment of isolated structures for patents enables efficient asset accumulation, which directly impacts the amount of net equity minus all debt obligations. Analyzing fluctuations in book capitalization allows investors to assess the real growth of the company's assets without market noise, eliminating the risk of investing in impaired assets with low fundamental value.

Competitors of Impact BioMedical Inc

HLN: Total Stockholders' Equity|Company Book Value Kenvue Inc. (KVUE)|veronapharma.com (VRNA) - Net Asset Value|MENS - Book Capitalization|Accounting Value of Company Ligand Pharmaceuticals Incorporated|Book Capitalization AMRX|Book Capitalization PRGO (Perrigo Corp)|Company Book Value Alvotech|liquidia.com - Accounting Value of Company|GLPG: Company Book Value|ANIP - Company Net Assets|MNKD: Book Capitalization|Book Capitalization Amphastar Corp|PCRX - Company Net Assets|Accounting Value of Company SPRY|Theravance Biopharma, Inc. - Company Book Value|Total Stockholders' Equity Aquestive Therapeutics Inc AQST|Company Net Assets scPharmaceuticals (SCPH)|Total Net Assets Tectonic Therapeutic Inc. TECX|Book Capitalization Tonix Pharmaceuticals (TNXP)|SXTC - Accounting Value of Company|Book Capitalization EPRX|BHST (BioHarvest Sciences, Inc.) - Total Stockholders' Equity|EXOZ - Company Book Value|Accounting Value of Company Oramed Pharma|ENTX (Entera Bio Ltd.) - Book Capitalization|Book Valuation of Business HYFT (ipatherapeutics.com)|ABVC BioPharma, Inc. - Company Book Value|Cumberland Pharmaceuticals Inc - Company Net Assets|Company Book Value Quantum BioPharma Limited|FGEN - Net Asset Value|TELO: Book Capitalization|Rani Therapeutics Holdings, Inc. (RANI) - Book Capitalization|Book Capitalization SNYR|Company Net Assets Rallybio Corp. (RLYB)|Company Net Assets Lexaria Bioscience|Total Net Assets Pulmatrix Corporation PULM|Company Net Assets Pheton Holdings|Accounting Value of Company Aptorum Group Ltd APM|LYRA - Book Capitalization|TNFA - Company Book Value|cbdmd.com - Book Capitalization|PRFX (PainReform Corp) - Book Valuation of Business|Company Book Value CYTO (Altamira Therapeutics Ltd)|Total Stockholders' Equity LIPO|Company Book Value OPTN (OptiNose)|Company Net Assets Pieris Pharmaceuticals Inc (PIRS)|PROC: Book Capitalization|Total Stockholders' Equity Petros Pharma PTPI|Qilian International (QLI) - Book Capitalization|SLRN - Accounting Capitalization|TFF Pharmaceuticals, Inc. - Book Capitalization